Summary.-Subcellular fractions from an aminoazo dye induced rat hepatoma (D23) were examined for their ability to evoke rejection responses in syngeneic hosts to transplanted tumour cells and to induce the production of humoral antibody. Membrane fractions isolated by zonal centrifugation and displaying an increased activity of tumour specific antigen , as well as crude membrane fractions and purified tumour cell ghosts, all elicited tumour specific antibody demonstrable by membrane immunofluorescence staining of viable hepatoma D23 cells. Tumour cell nuclei or soluble cytoplasmic protein were, however, lacking in this capacity. Resistance to tumour cell challenge was not observed in rats treated with any of the hepatoma D23 subcellular fractions administered by various routes either alone or in admixture with bacterial adjuvants. These findings are relevant to current views that tumour immunity may be more optimally achieved by inoculation of intact (viable or attenuated) tumour cells.
IMMUNITY to transplanted tumours in syngeneic hosts can be induced by prior treatment of the recipients with tumour cells prevented from progressive growth (reviewed by Baldwin, 1973) . This type of immunization has frequently been carried out using tumour cells attenuated by radiation or treatment with cytotoxic drugs, but a more effective response is often achieved following exposure to viable tumour cells. This was originally demonstrated in studies showing the development of tumour immunity following surgical resection of tumour grafts (Prehn and Main, 1957) and is further emphasized by the expression of concomitant immunity in the tumour bearing host (Baldwin, 1973) . Also, it has been shown that the tumour immune response elicited with viable 3-methylcholanthrene induced rat sarcoma cells in admixture with B.C.G. is much greater than that produced when radiation attenuated cells are used (Baldwin and Pimm, 1973) . These approaches, however, impose serious limitations in designing suitable protocols for immunotherapy since administration of viable tumour cells, even in admixture with bacterial adjuvants, may not be acceptable and there are logistic problems in the use of attenuated tumour cells. From these considerations, it is clearly desirable to employ cell-free tumour antigen preparations and the studies reported here were designed to examine the immunogenicities of isolated aminoazo dye induced rat hepatoma membrane fractions, isolated as described in the previous paper . These fractions retain tumour specific antigen, as defined by their capacity to interact with tumour specific antibody and, in this report, have been further examined for their capacity both to induce tumour rejection immunity as well as specific humoral antibody responses.
MATERIALS AND METHODS
Tumour and tumour cell fractionation.-Details of the preparation of hepatoma D23 membrane fractions and nuclei are described in the previous paper Representative tests performed to evaluate the immunogenicity of isolated membrane fractions of hepatoma D23 are summarized in Tables I and II . In these tests, the effectiveness of subcellular fractions in conferring transplantation resistance to tumour cell challenge may be compared with the protective effect elicited by immunization with y irradiated hepatoma D23 cells (Table I) . Also, in order to detect any low levels of resistance, challenge doses of between 1 and 5 x 103 hepatoma cells were chosen since these represent the minimum doses necessary to produce consistent tumour growth -in untreated control animals.
Immunization with the antigenic membranes isolated by A-XII or B-XIV zonal centrifugation of hepatoma D23 homogenates induced marked humoral antibody responses essentially comparable with that obtained following immunization with radiation attenuated tumour cells (Table II) . No protection, however, was afforded to treated rats following challenge with low doses of hepatoma D23 cells (1-3 x 103 cells) and the outgrowth of tumours in immunized and untreated rats was essentially equivalent (Table I) . Although the membranes in these tests were isolated from the nuclear sediment (1000 g pellets) of hepatoma homogenates, purified nuclei lacked the capacity to induce humoral antibody formation and no significant protection to tumour cell challenge was observed in treated rats (Tables I and II) . Wolf and Avis (1970) have indicated that the size of plasma membrane fragments is critical in the induction of immunity to a carcinogen induced murine lymphoma and greatest protection against viable tumour cell challenge was produced by immunization with almost intact cell ghost preparations rather than fragmented surface membranes. In order to investigate this, cell ghosts were prepared from single cell suspensions of hepatoma D23 according to the method of Warren et al. (1966) using fluorescein mercuric acetate to stabilize the plasma membrane during cell disruption. By phase contrast microscopy, the membranes isolated using this technique appeared as large empty bags ( Fig.) and often a lesion through which the nucleus and cytoplasm were expelled was distinguishable. As indicated in Table  I , immunization with up to 6 9 x 107 hepatoma D23 cell ghosts produced no protection against challenge with 2 x 103 viable tumour cells. It is evident that treatment of cell membranes with the sulphydryl blocking reagent fluorescein mercuric acetate did not grossly inactivate hepatoma D23 specific antigen since treated rats responded to immunization by the production of significant levels of humoral antibody detectable by membrane immunofluorescence staining of viable target cells (Table II) .
In Experiments 12-23, the effects of administration of the hepatoma D23 membranes by various routes and with or without adjuvant were compared (Table I) . The membrane fractions used in these tests were isolated as extranuclear membranes (ENM) either following mechanical homogenization of hepatoma D23 tissue, as already described for the preparation of tumour membranes by A-XII zonal centrifugation or by the method of Baldwin and Moore (1969) . The predominant response to immunization by the intradermal, subcutaneous or footpad routes was again the production of humoral antibody (Table II) although treated rats showed no significant resistance to challenge with viable hepatoma D23 cells (Table I) (Table I) . The soluble cytoplasmic protein fraction which has been shown to be lacking in tumour specific antigen (Baldwin and Moore, 1969) failed to induce significant tumour protection (Table I) and also to elicit a humoral antibody response demonstrable by the immunofluorescence staining of hepatoma D23 target cells (Table II) .
DISCUSSION
Immunization of syngeneic rats with membrane preparations isolated from rat hepatoma D23, as well as intact cell ghosts consistently elicited tumour specific antibody, but treated rats were unable to reject challenges with hepatoma D23 cells at a dose only just sufficient to produce progressive growth in controls. These findings are comparable with the data already published on the immunogenicity of crude hepatoma membrane fractions (Baldwin, Embleton and Moore, 1973b) where the principal response was the development of humoral antibody, with a weak cell mediated reaction, and rats did not reject a subsequent challenge with viable tumour cells. In the present studies, subcellular fractions (nuclei and soluble cytoplasmic protein) which are considered to be lacking in hepatoma D23 specific antigen as assessed by in vitro assay (Baldwin and Moore, 1969; Price and Baldwin, 1974) did not elicit antibody formation in treated rats, indicating that these two methods for antigen detection showed good correlation.
None of the variants introduced in the present investigation, including the use of membrane fractions with a higher specific antigenic activity, or the incorporation of adjuvants such as B.C.G., modified the type of immune response and the overall effect was essentially nonprotective against subsequent tumour challenge. The lack of immunoprotection by subcellular fractions in the rat hepatoma system contrasts with the resistance conferred by subcellular materials demonstrable with polycyclic hydrocarbon or alkylnitrosamine induced tumours in the mouse (Pilch, 1968; McCollester, 1970; Wolf and Avis, 1970) and guinea-pig (Oettgen et al., 1968; Holmes, Kahan and Morton, 1970; Meltzer et al., 1972) . In these studies, membrane fractions (Pilch, 1968; McCollester, 1970; Wolf and Avis 1970) and solubilized membrane extracts (Pilcb, 1968; Holmes et al., 1970; Meltzer et al., 1972) as well as the soluble fraction of tumour homogenates (Oettgen et al., 1968) (Parish, 1971a, b; Shirrmacher and Wigzell, 1972; Thompson et al., 1972) . However, in attempting a similar manipulation of the immune system, Levy et al. (1974) observed that acetoacetylation of soluble tumour extracts did not increase the effectiveness of this material to protect mice against subsequent challenge with 3-methylcholanthrene induced sarcoma cells.
The predominant response to hepatoma membrane immunization is the production of humoral antibody and other studies have established that hepatoma D23 antigen isolated as a soluble component, either by enzymic digestion of cell membranes (Baldwin and Glaves, 1972; Baldwin et al., 1974) or from tumourbearer serum (Baldwin et al., 1973a ) also induces tumour specific antibody without the development of protection to tumour cell challenge (unpublished findings). These observations are relevant to the role of circulating tumour antigen in the tumour bearing host since humoral antibody responses to acellular tumour antigens may modify tumour rejection reactions (Baldwin et al., 1973c) . This has already been demonstrated in experiments where rats pre-immunized with membrane fractions of hepatoma D23 failed to elicit a tumour rejection reaction after treatment with irradiated hepatoma D23 cells (Baldwin et al., 1973b) . This type of observation may be comparable with immunological enhancement phenomena where prolonged survival of allografts (Ranney et al., 1973; Sumerska et al., 1974) or allogeneic tumour cells (Rosenberg et al., 1973) has been demonstrated following pre-treatment with acellular transplantation antigens. Tables  I and II. 
